From: Bilateral benign renal oncocytomas and the role of renal biopsy: single institution review
Patient | Age* | Pre-op Creatinin e (mg/dL) | Pre-op eGFR† | Pre-op CKD (Category)† | Follow-up after PN (months**) | Follow-up Creatinine (mg/dL) | Follow-up eGFR† | Post-op CKD (Category)† | Change in eGFR† |
---|---|---|---|---|---|---|---|---|---|
1 | 55–60 | 0.7 | 104 | G1 | 3.9 | 0.8 | 100 | G1 | -3.8% |
2 | 65–70 | 0.8 | 75 | G2 | 24.0 | 0.9 | 64 | G2 | -14.7% |
3 | 65–70 | 1.0 | 77 | G2 | 19.6 | 1.1 | 68 | G2 | -11.7% |
4 | 70–75 | 0.8 | 88 | G2 | 49.3 | 0.8 | 86 | G2 | -2.3% |
5 | 65–70 | 0.9 | 87 | G2 | 69.2* | 1.6 | 42 | G3b | -51.7% |
6 | 60–65 | 0.7 | 102 | G1 | 55.1 | 1.2 | 63 | G2 | -38.2% |
7 | 75–80 | 0.9 | 62 | G2 | 64.7 | 1.3 | 38 | G3b | -38.7% |
8 | 65–70 | 1.4 | 51 | G3a | 19.4 | 1.3 | 55 | G3a | +7.8% |
9 | 45–50 | 1.0 | 90 | G1 | 125.3* | 1.0 | 84 | G2 | -6.7% |
10 | 65–70 | 1.0 | 79 | G2 | 43.0 | 1.2 | 61 | G2 | -22.8% |
11 | 75–80 | 1.3 | 53 | G3a | 2.5 | 1.3 | 53 | G3a | 0% |
12 | 65–70 | 0.9 | 87 | G2 | 0.2 | 1.1 | 69 | G2 | -20.7% |